Related Experiment Video
Updated: Sep 4, 2025
A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
Published on: March 24, 2023
Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing
Hadley Johnson1, Brandon L Adler1, JiaDe Yu1
1Ms. Johnson is from the University of Minnesota Medical School, Minneapolis. Dr. Adler is from the Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles. Dr. Yu is from the Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston.
Abstract:
Allergic contact dermatitis (ACD) has been estimated to affect up to 20% of the general population. Patch testing is the gold standard for identification of causative allergens. When allergen avoidance fails, current treatment options include topical and oral corticosteroids, systemic immunosuppressants, and phototherapy. Dupilumab, a monoclonal antibody targeting IL-4/IL-13, is approved by the US Food and Drug Administration for the treatment of moderate to severe atopic dermatitis. It also has been used off label with some success in the treatment of ACD. This article discusses the evidence for using dupilumab to treat ACD as well as considerations for patch testing in patients who are taking this medication.
